期刊文献+

昔布类药物的临床安全性研究 被引量:1

下载PDF
导出
摘要 目的:评价昔布类药物的临床安全性。方法:综述近年来国内外关于昔布类药物临床安全性的文献与报道,分别对全球已上市的六种昔布类药物进行安全性评价。结果:昔布类药物有增加心血管事件的风险,但它们的类效应强度不同,合理选择使用利大于弊。
出处 《黑龙江医药》 CAS 2009年第6期875-876,共2页 Heilongjiang Medicine journal
  • 相关文献

参考文献8

二级参考文献33

  • 1FDA announces a series of changes to the class of marketed non-steroidal anti-inflammatory drugs (NSAIDs). www. fda.gov/bbs/topics/news/2005/NEW01171. html , 2005-04-07/2005 -05.
  • 2COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). www. fda. gov/cder/drug/infopage/ COX2/ default. htm ,2005-04-07/2005-05.
  • 3Questions and Answers: FDA Regulatory Actions for the COX-2 Selective and Non-Selective Non-Steroidal Anti-inflammatory drugs ( NSAIDs ) . www. fda. gov/cder/drug/infopage/ COX2/ CO X2qa. htm ,2005-04-07/2005-05.
  • 4FDA Public Health Advisory: FDA Announces Important Changes and Additional Warnings for COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs(NSAIDs ). www. fda. gov/cder/drug/advisory/COX2. htm,2005 -04-07/2005 -05.
  • 5.国家食品药品监督管理局密切关注非甾体类抗炎药物的安全性问题[EB/OL].http://www.sfda.gov.cn/cmsweb/webportal/W1/search. html,2005-04-12/2005-05.
  • 6European Medicines Agency announces regulatory action on COX-2 inhibitors. http ://www. emea. eu. int/htms/hotpress/d6275705. htm, 2005-04-17/2005-05.
  • 7European Medicines Agency statement on the suspension of use of Bextra. http://www. emea. eu. int/htms/hotpress/h12163705. htm, 2005-04-12/2005-05.
  • 8Media Releases Stringent Conditions for COX-2 Inhibitors.http ://www. medsafe. govt. hz/hot/media/2005/COX2April05. htm, 2005-04 -29/2005-05.
  • 9Health Canada has asked Pfizer to suspend sales of its drug BextraTM and informs canadians of new restrictions on the use of Celebrex (R). http://www. hc-sc. gc. ca/english/media/releases/2005 / statement_drug_safety. html , 2005-04-07/2005-05.
  • 10Expanded information on Cox-2 inhibitors for doctors and pharmacists (amended * ). http://www. tga. gov. au/media/2005/050214_cox2. htm#pdf , 2005-04-14/2005-05.

共引文献31

同被引文献17

  • 1Bombardier C,Laine L,Reicin A,et al.Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.VIGOR Study Group[J].N Engl J Med,2000,343(21):1520.
  • 2Winkelmayer WC,Waikar SS,Mogun H,et al.Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury[J].Am J Med,2008,121(12):1092.
  • 3Brune K,Hinz B.Selective cyclooxygenase-2 inhibitors:similarities and differences[J].Scand J Rheumatol,2004,33(1):1.
  • 4McAdam BF,Catella-Lawson F,MardinilA,et al.Systemic biosynthesis of prostacyclin by cyclooxygenase(COX)-2:the human pharmacology of a selective inhibitor of COX-2[J].Proc Nati Acad Sci USA,1999,96(1):272.
  • 5Scheiman JM,Yeomans ND,Talley NJ,et al.Prevention of ulcers by esomeprazole in at risk patients using nonselective NSAIDs and COX-2 inhibitors[J].Am J Gastroenterol,2006,101(4):701.
  • 6Nussmeier NA,Whelton AA,Brown MT,et al.Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery[J].N Enql J Med,2005,352(11):108.
  • 7Paech MJ,Salman S,Llett KF,et al.Transfer of parecoxib and its primary active metabolite valdecoxib via transitional breastmilk following intravenous parecoxib use after cesarean delivery:a comparison of naive pooled data analysis and nonlinear mixed-effects modeling[J].Anesth Analg,2012,114(4):837.
  • 8White WB,West CR,Borer JS,et al.Risk of cardiovascular events in patients receiving celecoxib:a metaanalysis of randomized clinical trials[J].Am J Cardiol,2007,99(1):91.
  • 9Sakamoto C,Soen S.Efficacy and safety of the selective cyclooxygenase-2inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan[J].Digestion,2011,83(l-2):108.
  • 10Trelle S,Reichenbach S,Wandel S,et al.Cardiovascular safety of non-steroidal anti-inflammatory drugs:network meta-analysis[J].BMJ,2011,342:c7086.

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部